We were delighted to catch up with our Editorial Board member, Prof. Toby Maher (University of Southern California, Los Angeles, CA, USA) during the ERS Virtual Congress, to discuss the ISABELA study in IPF (NCT03711162) and the challenges the trial has faced during the COVID-19 pandemic.
- What are the major unmet needs in the treatment of idiopathic pulmonary fibrosis (IPF)? (0:11)
- Could you tell us a little about ziritaxestat and its mechanism of action? (1:30)
- Could you give us an overview of the ISABELA clinical trial program and its findings to date? (2:28)
- What are the next steps in the clinical development of ziritaxestat? (3:46)
- What are the major challenges of conducting IPF clinical trials in the era of COVID-19? (5:07)
Speaker disclosure: Toby Maher has acted as a consultant and speaker for Boehringer Ingelheim, Galapagos and Roche.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the ERS International Congress 2020.
Share this Video
Related Videos In Idiopathic pulmonary fibrosis
Vincent Cottin, ERS 2021: Challenges and Latest Research in Idiopathic Pulmonary Fibrosis
We were delighted to catch up with Professor Vincent Cottin (National Reference Centre for Rare Pulmonary Diseases, Lyon, France) to discuss the challenges associated with investigating rare diseases and the hot topics in idiopathic pulmonary fibrosis. Questions What are the challenges associated with clinical trials investigating rare diseases such as idiopathic pulmonary fibrosis (IPF)? (0:20) […]
Vincent Cottin, ERS 2021: GLPG1205 for Idiopathic Pulmonary Fibrosis
Professor Vincent Cottin (National Reference Centre for Rare Pulmonary Diseases, Lyon, France) spoke with touchRESPIRATORY around the Phase 2 PINTA study, investigating GLPG1205 for idiopathic pulmonary fibrosis. The abstract ‘Results of a phase 2 study of GLPG1205 for idiopathic pulmonary fibrosis (PINTA).’ (Presentation ID 2904) was presented at ERS International Congress 2021, 5-8 September 2021. […]
Rebecca Bascom, ATS 2021: MN-001 in Idiopathic Pulmonary Fibrosis
We were delighted to talk with Dr Rebecca Bascom (Penn State Hershey Medical Center, Hershey, PA, US) around her study investigating the use of MN-001 in patients with idiopathic pulmonary fibrosis. ‘A Single-Center, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of MN-001 (Tipelukast) in Subjects with Idiopathic Pulmonary Fibrosis.‘ was presented at […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!